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(71%) with non-LPD (mostly bicalutamide 62%) in first line. In the non-LPD sub-
group, LPD was postponed in 712 patients. The LPD subgroup had frequent bone
metastases, worse ECOG and, higher LDH, ALP and PSA at the start of first line ther-
apy. 36% of all patients experienced a SSE during follow-up (32% RT to the bone, 4%
surgery to the bone, 4% pathological fracture and 6% SCC). There was a small differ-
ence in total SSEs between subgroups (39% for LPD vs 35% for non-LPD, p¼ 0.064).
Median SSE-free survival was 13.0 vs 21.2 months for LPD and non-LPD respectively
(HR 1.626, p¼ 0.007). Correction for prognostic factors showed that type of first line
therapy (LPD/non-LPD) was not associated with SSE-free survival (HR 1.021,
p¼ 0.817). Worse ECOG and presence of bone metastases were significant predictors
for worse SSE-free survival.
Conclusions: Approximately 40% of CRPC-patients developed a SSE during follow-
up. Worse patient and disease characteristics probably influenced timing of LPD. These
factors were also related with worse SSE-free survival. Delay in the initiation of a LPD at
castration-resistant state does not appear to influence outcome related to time-to-SSE.
Clinical trial identification: The CAPRI study is registered in the Dutch Trial Registry
as NTR3591.
Legal entity responsible for the study: Institute for Medical Technology Assessment,
Erasmus University Rotterdam.
Funding: The CAPRI registry was funded by Sanofi-Aventis Netherlands B.V., Janssen-
Cilag B.V., Astellas Pharma B.V., and Bayer B.V. The funding organizations had no role
in the design and conduct of the study, collection, management, analysis, interpretation
of the data, and preparation, review, or approval of the abstract.
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Background: Androgen levels are associated with overall survival (OS) in mCRPC. Doc
impairs microtubules and has AR inhibitory effects. This analysis evaluates change in
androgen levels (Testosterone (T), Androstenedione (A) and DHEA (D) and outcome
in Doc-treated mCRPC patients.
Methods: Data from 1,050 men treated on CALGB 90401 with Doc, prednisone and
either B or placebo were used. Pre-treatment, 6 week and progression serum assays for
T, A and D were performed via tandem Liquid Chromatography-Mass Spectrometry
(LC-MS/MS). Ratio of change in androgen (6 week value /baseline value) was calcu-
lated. Decline was further evaluated as high or low (> or<median decline for all
patients). The logistic regression and proportional hazards models were used to assess
the prognostic significance of changes in T, A, and D in predicting PSA response, PFS
and OS adjusting for known prognostic factors.
Results: Median values for baseline T, A, and, D were 1.0, 13.5 and 8.1, ng/dL respec-
tively, while androgen levels at 6 weeks were 0.64, 7.0 and 6.8, ng/dL respectively. At 6
weeks a decline in all three androgens was observed. The ratio of 6weeks/baseline in T,
A and D were 0.93, 0.56 and 0.86, respectively. There was interaction between levels of
T decline and treatment arm (p-value¼0.047). Among 291 patients with high levels of
T decline, those who also received B were more likely to experience a 50% decline in
PSA (87%) compared to those who did not receive B (67%,). Associations between
androgen decline and PFS were NS. In multivariable analysis adjusting for prognostic
factors, the hazard ratio (HR) for OS demonstrated that decline in T at 6-weeks/base-
line was associated with longer OS, HR 1.02 (95% CI 1.01 ,1.03 p¼ 0.001). Median OS
for low T change (ratio>¼0.93) is 20.9 mos vs 26.3 mos for high T change (<0.93).
Conclusions: Patients treated with Doc who experience a greater drop in T on therapy
experience a significantly longer OS and higher rate of PSA decline but no effect on
PFS. B and androgen decline may confer interacting beneficial effects. Data are consis-
tent with the favorable prognostic significance of higher serum androgens in the CRPC
setting and reflecting the potential effect of Doc on AR signalling.
Clinical trial identification: NCT00110214.
Legal entity responsible for the study: Alliance for Clinical Trials in Oncology.
Funding: National Cancer Institute: R21 CA195424-01, U10CA180821, U10CA180882.
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Background: Cabazitaxel (CAB) has been shown in the TROPIC trial to improve over-
all survival (OS) in mCRPC patients after docetaxel (DOC). However clinical trial pop-
ulations may not reflect the real world population. The objective is to compare patient
characteristics and outcome of CAB within clinical trials and in standard of care (SOC)
from data extracted from the CAPRI registry.
Methods: CRPC pts treated with CAB directly after DOC, before 1-1-2017, either
within a clinical trial or as SOC were retrospectively identified and followed to 1-1-
2018. For multivariable analyses, missing values were imputed by multiple imputation
using the Monte Carlo Markov Chain method.
Results:
Table: 817P Baseline characteristics at start cabazitaxel (baseline
period defined as 42 days before to 7 days after start of cabazitaxel).








Age (years) Median (IQR)
75 years (%)
68 (64-72) 17 67 (64-72) 13 0.502
Period on ADT (months)
Median (IQR)
25 (18-37) 30 (19-45) 0.091
ALP (U/L) Median (IQR)
Missing (%)
222 (100-360) 18 192 (97-366) 11 0.799
PSA (ug/L) Median (IQR)
Missing (%)




7.1 (6.3-7.8) 17 7.7 (6.7-8.1) 11 0.029
LDH (U/L) Median (IQR)
Missing (%)
328 (252-504) 26 268 (209-397 14) 0.010
ECOG performance (%) 0 1
>1 Missing
16 49 9 27 23 56 3 17 0.186
Visceral disease (%) No Yes
Missing
29 19 52 45 11 44 0.038
Opioid use (%) No Yes
Missing
23 28 50 41 27 33 0.140
Symptoms (%) No Yes
Missing
6 78 16 17 72 11 0.033
Docetaxel cycles Median
(IQR) Missing (%)
7 (5-10) 1 10 (7-10) 3 0.002
Time since last docetaxel
dose (months) Median
(IQR) <6 months (valid
%) Missing (%)
2.2 (0.9-4.7) 86 5 3.9 (2.0-6.0) 74 5 0.001
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From a total of 3,616 pts in the CAPRI database, we identified 356 pts treated with
CAB, of which 173 pts were treated directly post-DOC. Trial pts had less symptoms and
visceral disease, lower LDH, higher hemoglobin, received more DOC cycles and had a
longer treatment-free interval since last DOC (see Table). The median number of CAB
cycles was higher in trials compared to SOC (5 vs 4, p¼ 0.031). Median OS was 13.6 vs
9.6 months for trial pts and SOC, respectively (HR 0.73, p¼ 0.07). PSA response (
50% decline) was 27 vs 11%, respectively (p¼ 0.210). However, after correction for
prognostic factors, trial participation did not retain statistical significance (HR 0.94,
p¼ 0.73), but longer period on ADT, lower LDH and absence of visceral metastases
were significant for better OS. In addition, lower PSA and absence of symptoms had a
trend for better OS.
Conclusions: The OS in the trial subgroup is in agreement with the OS of the TROPIC
trial in a contemporary real world setting. However, the SOC pts had a trend for worse
OS which may be explained by worse prognostic factors at CAB initiation. Accordingly,
pts whose disease has progressed post-DOC should be carefully selected for treatment
to ensure optimal outcomes.
Clinical trial identification: The CAPRI study is registered in the Dutch Trial Registry
as NTR3591.
Legal entity responsible for the study: Institute for Medical Technology Assessment,
Erasmus University Rotterdam.
Funding: The CAPRI registry was funded by Sanofi-Aventis Netherlands B.V., Janssen-
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in the design and conduct of the study, collection, management, analysis, interpretation
of the data, and preparation, review, or approval of the abstract.
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Background: Cabazitaxel is approved for patients with mCRPC, post docetaxel. The
CUP (CABAZ_C_05005) and EAP (NCT01254279) provided access to cabazitaxel
before commercial availability and assessed real-world safety. CAPRISTANA
(CABAZC 06092), a prospective, observational study, evaluated the routine clinical use
of cabazitaxel. In this analysis we examined factors associated with cabazitaxel treat-
ment duration in a real-life setting.
Methods: Patients18 years of age with mCRPC previously treated with docetaxel,
received cabazitaxel 25 mg/m2 intravenously every 3 weeks until disease progression,
death, unacceptable toxicity or physician/patient decision. Of note, treatment was
capped at 10 cycles in some countries.
Results: The CUP/EAP/CAPRISTANA studies combined included 1,621 patients
(CUP/EAP, N¼ 1,432; CAPRISTANA, N¼ 189). The median number of cabazitaxel
cycles received was 6. Overall, 708 patients (43.7%) received>6 cycles (Table); 211
(13.0%) received>10 cycles. For patients receiving>10 cycles, the median number of
cabazitaxel cycles received was 14. Patients receiving more cabazitaxel cycles tended to
have better ECOG performance status of 0–1 (Table; P¼ 0.0017 for6 vs> 6 cycles).
In total, 348 patients (21.5%) were75 years of age, of which 40% (n¼ 139) received
>6 cabazitaxel cycles. Further analysis into the patient subgroups and reasons for treat-
ment discontinuation are ongoing.
Conclusions: Cabazitaxel was well tolerated by patients across these global studies,
including elderly patients. Many patients derived benefit from cabazitaxel and went on
to receive a greater number of cycles. Further analyses may identify prognostic factors
that could indicate which patients are likely to receive>6 cabazitaxel cycles and derive
greater benefit. Funding: Sanofi.
Clinical trial identification: Compassionate Use Program (CUP): CABAZ_C_05005.
Expanded Access Program (EAP): NCT01254279. CAPRISTANA Registry Study:
CABAZC 06092.
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Table: 818P
Median age, years (range) 68.0 (42–89) 68.0 (43–89)
Age, n (%) <65 years 65–75 years 75 years 271 (29.7) 433 (47.4) 209 (22.9) 230 (32.5) 339 (47.9) 139 (19.6)
ECOG PS, n (%) 0–1 2* N¼ 912 816 (89.5) 96 (10.5) N¼ 708 665 (93.9) 43 (6.1)
Median cabazitaxel cycles, n (range) 4 (1–6) 10 (7–49)
Median duration of cabazitaxel exposure, months (range) 2.8 (1–6) 6.9 (5–35)
Median time from prostate cancer diagnosis, years (range) 4.5 (0–22) 4.7 (0–20)
Median time from mCRPC diagnosis, years (range) 1.7 (0–14) 1.8 (0–12)
Median docetaxel cycles at last administration, n (range) 7 (1–69) 8 (1–58)
Metastatic sites, n (%) Bone Visceral Regional lymph nodes N¼ 912 829 (90.8) 47 (5.1) 282 (30.9) N¼ 707 630 (89.0) 23 (3.2) 214 (30.2)
G-CSF during Cycle 1, n (%) Prophylactic Therapeutic Both N¼ 499 385 (42.2) 69 (7.6) 45 (4.9) N¼ 380 314 (44.4) 33 (4.7) 33 (4.7)
Pain at baseline (CAPRISTANA study only), n (%) None Moderate Severe N¼ 86 15 (17.4) 63 (73.3) 8 (9.3) N¼ 68 18 (26.5) 47 (69.1) 3 (4.4)
*Includes one patient with ECOG PS 3 receiving 6 cabazitaxel cycles.
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